Applying GRADE for diagnosis 79 2 Rodrigo, 2011 [9] Author Rodrigo Year of publication 2011 Journal Clinical & Experimental Allergy Study design Systematic review Study population 16 double-blind placebo-controlled RCTs involving 5348 patients with allergic rhinitis. Of them, 7 studies with 2589 patients with seasonal allergic rhinitis, and 9 studies with 2759 patients with perennial allergic rhinitis. 13 studies were carried out in adults and children > 12 years. 3 studies were carried out in children. Description of the intervention (including dosage and duration) Fluticasone furoate nasal spray 110 µg once daily Description of control group Placebo Outcome measures Mean change in daily reflective total ocular symptom score (rTOSS), mean change in AM pre-dose instantaneous total ocular symptom score (iTOSS), mean change in daily reflective nasal symptom score (rTNSS), mean change in AM pre-dose instantaneous total nasal symptom score (iTNSS), individual nasal and ocular symptoms, overall evaluation of response to therapy, quality of life (rhinoconjunctivitis quality of life questionnaire (RQLQ)), adverse events Effect on outcome measures (nasal / ocular symptoms, concentration, sleep problems, absenteeism from school / work, quality of life) Mean change in daily reflective total ocular symptom score (rTOSS): Seasonal allergic rhinitis: MD: -0.54 (95%CI: -0.70 to -0.37) (6 studies, 2219 patients). Perennial allergic rhinitis: MD: -0.33 (95%CI: -0.61 to - 0.05) (3 studies, 919 patients). Eye itching/burning: Seasonal allergic rhinitis: MD: -0.20 (95%CI: -0.29 to -0.11) (3 studies, 886 patients). Perennial allergic rhinitis: MD: -0.14 (95%CI: -0.27 to -0.01) (2 studies, 604 patients). Eye tearing/watering: Seasonal allergic rhinitis: MD: - 0.22 (95%CI: -0.31 to -0.13) (3 studies, 886 patients). Perennial allergic rhinitis: MD: -0.11 (95%CI: -0.21 to -0.01) (2 studies, 604 patients). Eye redness: Seasonal allergic rhinitis: MD: -0.21 (95%CI: - 0.30 to -0.12) (3 studies, 886 patients). Perennial allergic rhinitis: MD: -0.11 (95%CI: -0.19 to -0.09) (2 studies, 604 patients). Mean change in daily reflective total nasal symptom score (rTNSS): Seasonal allergic rhinitis: MD: -1.14 (95%CI: -1.57 to -0.72) (6 studies, 2589 patients). Perennial allergic rhinitis: MD: -0.83 (95%CI: -1.08 to -0.59) (7 studies, 2539 patients). Rhinorrhea: Seasonal allergic rhinitis: MD: -0.35 (95%CI: -0.48 to -0.22) (4 studies, 1141 patients). Perennial allergic rhinitis: MD: -0.20 (95%CI: -0.32 to -0.07) (4 studies, 1054 patients). Nasal congestion: Seasonal allergic rhinitis: MD: -0.31 (95%CI: -0.40 to -0.23) (4 studies, 1141 patients). Perennial allergic rhinitis: MD: - 0.16 (95%CI: -0.24 to -0.09) (4 studies, 1054 patients). Nasal itching: Seasonal allergic rhinitis: MD: -0.31 (95%CI: -0.39 to -0.22) (4 studies, 1141 patients). Perennial allergic rhinitis: MD: -0.22 (95%CI: -0.30 to - 0.14) (4 studies, 1054 patients). Sneezing: Seasonal allergic rhinitis: MD: -0.39 (95%CI: -0.48 to -0.31) (4 studies, 1141 patients). Perennial allergic rhinitis: MD: -0.25 (95%CI: -0.32 to -0.18) (4 studies, 1054 patients) Risk of bias (AMSTAR-2) Did the research questions and inclusion criteria for the review include the components of PICO? For yes: Population Intervention Comparator group Outcome Optional (recommended)
RkJQdWJsaXNoZXIy MTk4NDMw